These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 2436247

  • 1. Dose-dependent effects of deprenyl on CSF monoamine metabolites in patients with Alzheimer's disease.
    Sunderland T, Tariot PN, Cohen RM, Newhouse PA, Mellow AM, Mueller EA, Murphy DL.
    Psychopharmacology (Berl); 1987; 91(3):293-6. PubMed ID: 2436247
    [Abstract] [Full Text] [Related]

  • 2. Differential effects of clorgyline on catecholamine and indoleamine metabolites in the cerebrospinal fluid of rhesus monkeys.
    Garrick NA, Scheinin M, Chang WH, Linnoila M, Murphy DL.
    Biochem Pharmacol; 1984 May 01; 33(9):1423-7. PubMed ID: 6203542
    [Abstract] [Full Text] [Related]

  • 3. The effects of amiflamine on cerebrospinal fluid amine metabolites in the rhesus monkey.
    Garrick NA, Seppala T, Linnoila M, Murphy DL.
    Eur J Pharmacol; 1985 Mar 26; 110(1):1-9. PubMed ID: 2408906
    [Abstract] [Full Text] [Related]

  • 4. Monoamines and related metabolite levels in the cerebrospinal fluid of patients with dementia of Alzheimer type. Influence of treatment with L-deprenyl.
    Martignoni E, Bono G, Blandini F, Sinforiani E, Merlo P, Nappi G.
    J Neural Transm Park Dis Dement Sect; 1991 Mar 26; 3(1):15-25. PubMed ID: 1712206
    [Abstract] [Full Text] [Related]

  • 5. N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl.
    Karoum F.
    Br J Pharmacol; 1987 Feb 26; 90(2):335-45. PubMed ID: 3103805
    [Abstract] [Full Text] [Related]

  • 6. [Concentrations of monoamines and monoamine metabolites in cerebrospinal fluid determined by high-performance liquid chromatography with electrochemical detection].
    Yoshino K.
    No To Shinkei; 1982 Nov 26; 34(11):1099-106. PubMed ID: 6186264
    [Abstract] [Full Text] [Related]

  • 7. Tyramine pressor sensitivity changes during deprenyl treatment.
    Sunderland T, Mueller EA, Cohen RM, Jimerson DC, Pickar D, Murphy DL.
    Psychopharmacology (Berl); 1985 Nov 26; 86(4):432-7. PubMed ID: 3929314
    [Abstract] [Full Text] [Related]

  • 8. Phenylethylamine and monoamine metabolites in CSF of schizophrenics: effects of neuroleptic treatment.
    Beckmann H, Waldmeier P, Lauber J, Gattaz WF.
    J Neural Transm; 1983 Nov 26; 57(1-2):103-10. PubMed ID: 6194254
    [Abstract] [Full Text] [Related]

  • 9. Rhesus monkey cerebrospinal fluid amine metabolite changes following treatment with the reversible monoamine oxidase type-A inhibitor cimoxatone.
    Garrick NA, Seppala T, Linnoila M, Murphy DL.
    Psychopharmacology (Berl); 1985 Nov 26; 86(3):265-9. PubMed ID: 2412251
    [Abstract] [Full Text] [Related]

  • 10. Monoamine metabolite concentrations in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia.
    Palmer AM, Sims NR, Bowen DM, Neary D, Palo J, Wikstrom J, Davison AN.
    J Neurol Neurosurg Psychiatry; 1984 May 26; 47(5):481-4. PubMed ID: 6204017
    [Abstract] [Full Text] [Related]

  • 11. Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG concentrations after treatment with selective serotonin reuptake inhibitors.
    Sheline Y, Bardgett ME, Csernansky JG.
    J Clin Psychopharmacol; 1997 Feb 26; 17(1):11-4. PubMed ID: 9004051
    [Abstract] [Full Text] [Related]

  • 12. Monoamines and their metabolites in cerebrospinal fluid of patients with senile dementia of Alzheimer type using high performance liquid chromatography and gas chromatography-mass spectrometry.
    Parnetti L, Gottfries J, Karlsson I, Långström G, Gottfries CG, Svennerholm L.
    Acta Psychiatr Scand; 1987 May 26; 75(5):542-8. PubMed ID: 2440238
    [Abstract] [Full Text] [Related]

  • 13. CSF monoamine metabolite levels in Alzheimer's and Parkinson's disease.
    Gibson CJ, Logue M, Growdon JH.
    Arch Neurol; 1985 May 26; 42(5):489-92. PubMed ID: 2581531
    [Abstract] [Full Text] [Related]

  • 14. Repetitive measurement of monoamine metabolite levels in cerebrospinal fluid of conscious rats: effects of reserpine and haloperidol.
    Scheinin H, Scheinin M.
    Eur J Pharmacol; 1985 Jul 31; 113(3):345-51. PubMed ID: 2412847
    [Abstract] [Full Text] [Related]

  • 15. Monoamine metabolite levels in rat CSF: kinetic studies.
    Scheinin H, Scheinin M.
    Pharmacol Toxicol; 1987 Sep 31; 61(3):167-71. PubMed ID: 2446306
    [Abstract] [Full Text] [Related]

  • 16. Cerebrospinal fluid monoamine metabolites and neuropeptides in patients with panic disorder.
    Lepola U, Jolkkonen J, Pitkänen A, Riekkinen P, Rimón R.
    Ann Med; 1990 Sep 31; 22(4):237-9. PubMed ID: 1701091
    [Abstract] [Full Text] [Related]

  • 17. Monoamine metabolites in human cerebrospinal fluid: indicators of neuronal activity?
    Scheinin M.
    Med Biol; 1985 Sep 31; 63(1):1-17. PubMed ID: 2582215
    [Abstract] [Full Text] [Related]

  • 18. Concentrations of monoamine metabolites in the cerebrospinal fluid of twins and unrelated individuals--a genetic study.
    Oxenstierna G, Edman G, Iselius L, Oreland L, Ross SB, Sedvall G.
    J Psychiatr Res; 1986 Sep 31; 20(1):19-29. PubMed ID: 2423688
    [Abstract] [Full Text] [Related]

  • 19. Monoamine metabolites in cerebrospinal fluid and behavioral ratings in patients with early and late onset of Alzheimer dementia.
    Bråne G, Gottfries CG, Blennow K, Karlsson I, Lekman A, Parnetti L, Svennerholm L, Wallin A.
    Alzheimer Dis Assoc Disord; 1989 Sep 31; 3(3):148-56. PubMed ID: 2477044
    [Abstract] [Full Text] [Related]

  • 20. CSF monoamine metabolites and somatostatin in Alzheimer's disease and major depression.
    Molchan SE, Lawlor BA, Hill JL, Martinez RA, Davis CL, Mellow AM, Rubinow DR, Sunderland T.
    Biol Psychiatry; 1991 Jun 01; 29(11):1110-8. PubMed ID: 1714776
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.